Value of FOXP3 expression in prediction of neoadjuvant chemotherapy effect in triple-negative breast cancer
Background
Response of breast carcinoma to neoadjuvant chemotherapy (NAC) varies regarding many factors including hormonal receptor status. Breast cancer is a heterogenous disease with different outcomes, hence a need arises for new markers predicting the outcome of NAC especially for the triple-negative group when estrogen and progesterone receptors and HER-2/neu are negative. Forkhead box P3 (FOXP3) is a promising target with unclear role.
Aim
The aim was to examine the value of FOXP3 expression in locally advanced triple-negative breast cancer tumoral cells as well as tumor-infiltrating lymphocytes (TILs) and to elucidate its relation to the extent of NAC response.
Materials and methods
Forty-five cases of immunohistochemically confirmed triple-negative breast carcinoma were evaluated for NAC (doxorubicin; cyclophosphamide AC×four cycles+paclitaxel ×12 weeks; and patients with ejection fraction
Source: Egyptian Journal of Pathology - Category: Pathology Tags: Original Articles Source Type: research
More News: Breast Cancer | Breast Carcinoma | Cancer | Cancer & Oncology | Carcinoma | Chemotherapy | Egypt Health | Hormones | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy | Pathology